Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 77, Issue 1, 2016, Pages 77-88

  Quartino, Angelica L ^a   Hillenbach, Carina ^b   Li, Jing ^a   Li, Hanbin ^c   Wada, Russell D ^c   Visich, Jennifer ^a   Li, Chunze ^a   Heinzmann, Dominik ^b   Jin, Jin Y ^a   Lum, Bert L ^a  

^a GENENTECH INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Quantitative Solutions Inc   (United States)

Author keywords

Early breast cancer; Fixed dose; HER2; NONMEM; Population pharmacokinetics modeling; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BIOAVAILABILITY; BREAST NEOPLASMS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NONLINEAR SYSTEM; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SUBCUTANEOUS DRUG ADMINISTRATION; SYRINGE; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LOGISTIC MODELS; NONLINEAR DYNAMICS; RECEPTOR, ERBB-2; SYRINGES; TISSUE DISTRIBUTION; TRASTUZUMAB;

EID: 84954078054     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2922-5     Document Type: Article

References (26)

1. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26:60-70
2. Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232:123-138
3. Herceptin: Prescribing Information (2014) http://www.gene.com/download/pdf/herceptin-prescribing.pdf. Accessed 1 Oct 2014
4. Herceptin: Summary of Product Characteristics (2011) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000278/WC500074922.pdf. Accessed 1 Oct 2014
5. Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B (2013) Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol 53:192-201
6. F. Hoffmann-La Roche Ltd. Data on file
7. Bittner B, Richter WF, Hourcade-Potelleret F, McIntyre C, Herting F, Zepeda ML, Schmidt J (2012) Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung 62:401-409
8. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361-369
9. Charoin JE, Jacqmin P, Banken L, Lennon S, Jorga K (2004) Population pharmacokinetic analysis of trastuzumab (Herceptin) following long-term administration using different regimens. Population Approach Group in Europe (PAGE) 13: Abstract 489
10. Hourcade-Potelleret F, Lemenuel-Diot A, McIntyre C, Brewster M, Lum B, Bittner B (2014) Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab. CPT: Pharmacometrics Syst Pharmacol 3:e87
11. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:493-507
12. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251
13. Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C (2012) Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol 13:869-878
14. Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, Hillenbach C, Stroyakovskiy D, Lum BL, Elliott R, Weber HA, Ismael G (2015) Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol 26:320-325
15. National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed 12 Feb 2015
16. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648
17. FDA, Guidance for Industry: Population Pharmacokinetics (1999) http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf. Accessed 1 Oct 2014
18. R statistical software. http://www.r-project.org/
19. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20:511-528
20. Perl speaks NONMEM (PsN 3.4.2). http://psn.sourceforge.net/download.php#. Accessed 1 Oct 2014
21. Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 11:558-569
22. Mould DR, Sweeney KRD (2007) The pharmacokinetics and pharmacodynamics of monoclonal antibodies - mechanistic modeling applied to drug development. Curr Opin Drug Discov Dev 10:84-96
23. Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633-659
24. Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM (2010) Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 48:297-308
25. FDA (1998) Guidance for industry: pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf. Accessed 1 Oct 2014
26. Chames P, Van Regenmortel M, Weiss E, Baty D (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157:220-233